January 14, 2015 | The orthopedic pharmaceutical company PolyPid will revive its NASDAQ IPO, after it called off its previous offer in late 2014. The company published a revised prospectus to raised between $18-22 million, not including the underwriters’ commitment. The company hopes to reach a $80 million valuation in the IPO, with Aegis Capital acting as the chief underwriter along with Chardan Capital and MLV & Co. as secondary underwriters. PolyPid develops and markets a delayed-release treatment for compound bone fractures, which is scheduled to begin clinical trials in 2015, with hopes to enter the European market by 2017.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments